Price (delayed)
$24.96
Market cap
$1.71B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.29
Enterprise value
$1.56B
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing
There are no recent dividends present for ARVN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.